German pharmaceutical and laboratory equipment supplier, Sartorius plans to invest in a new production line for pallet tanks used in single-use bioreactors at its R&D facility in Bengaluru until 2027. This investment aims to meet both local and global demands.

Additionally, the company will nearly double its annual capacity for manufacturing and testing chromatography systems in 2025. With a $202 million R&D investment in 2024, Sartorius has allocated a significant portion to India, its largest global R&D site.

Chairman of Sartorius AG and Sartorius Stedim Biotech, Dr. Joachim Kreuzburg, highlighted India's crucial role in the company’s global network, serving both domestic and international markets. These investments would enhance its ability to offer cutting-edge solutions for biopharmaceutical manufacturing.

Sartorius’ India plant produces stainless steel components, bioreactor systems ranging from five litres to 6,500 litres, fermentation systems, and high-precision components for the biopharma industry. India also serves as a global hub for IT and digital solutions, focusing on software lifecycle management and development. Sartorius employs 700 people in India, with engineers comprising 45 percent of its workforce.